New injection shrinks sarcoma tumors in early trial
NCT ID NCT05755113
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests an experimental drug, tigilanol tiglate, injected directly into tumors in people with advanced soft tissue sarcoma that has spread. The goal is to see if it can shrink or destroy treated tumors. About 40 adults with tumors on the arms, legs, or body wall will take part.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SOFT TISSUE SARCOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Email: •••••@•••••
Locations
-
Memorial Sloan Kettering Cancer Centre
RECRUITINGNew York, New York, 10065, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a radioactive antibody light up hidden tumors?
- A simple blood test may reveal hidden infertility risk in young cancer survivors
- Could a massive tissue bank unlock sarcoma's secrets?
- Can a targeted pill stall advanced sarcomas?
- Protein-Wrapped chemo aims to hit tumors harder, spare healthy cells
- Drug duo takes on rare head and neck tumors